Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

This interventional trial (n=8) investigates the acceptability, feasibility, safety, and efficacy of Psilocybin-Assisted Psychotherapy (PAP/PAT) in treating Post-Traumatic Stress Disorder (PTSD) in military veterans.

Psilocybin, administered with psychotherapy, is examined as a potential breakthrough treatment for PTSD. Eight military veterans, aged 18-65, fluent in English, with internet access, and a PCL-5 score ≥33, will participate. The study involves two preparatory sessions, two psilocybin dosing sessions, and 12 sessions of Cognitive Processing Therapy.

The primary outcome measure is the reduction in PTSD symptoms, assessed by PCL-5 scores from baseline to one-month follow-up. The study is conducted in Surrey, United Kingdom, by Combat Stress, with Prof. Dominic Murphy as the principal investigator. The estimated study start is June 2023, with an estimated completion in August 2025.

Topic PTSD
Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.